tiprankstipranks
Advertisement
Advertisement

60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status

Story Highlights
  • In early 2026, 60 Degrees Pharmaceuticals faced a Nasdaq delisting notice after its stock traded below the $1.00 minimum bid price for 30 days.
  • By February 11, 2026, the company regained compliance with Nasdaq’s bid requirement, canceling a delisting hearing and preserving its Nasdaq Capital Market listing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status

Claim 30% Off TipRanks

60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) just unveiled an update.

On January 20, 2026, 60 Degrees Pharmaceuticals received notice from Nasdaq that its common stock and warrants were subject to delisting for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, prompting the company to request an appeal and temporarily stay the suspension of trading. On February 11, 2026, Nasdaq informed the company that it had regained compliance with the minimum bid price requirement, leading to the cancellation of a February 19, 2026 hearing and confirming that its common stock will continue to be listed and traded on the Nasdaq Capital Market.

The reversal of the delisting determination removes an immediate threat to 60 Degrees Pharmaceuticals’ market listing status and trading liquidity. This resolution stabilizes the company’s position on the Nasdaq Capital Market, which can support investor confidence and access to capital while closing out the compliance matter without further proceedings.

The most recent analyst rating on (SXTP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

Spark’s Take on SXTP Stock

According to Spark, TipRanks’ AI Analyst, SXTP is a Neutral.

The score is held down primarily by very weak fundamentals (outsized losses and ongoing cash burn) and a significant Nasdaq delisting risk. Technical signals are comparatively supportive, but valuation is constrained by continued unprofitability and no dividend support.

To see Spark’s full report on SXTP stock, click here.

More about 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. is a biopharmaceutical company whose common stock and warrants trade on the Nasdaq Capital Market. The company operates within the public equity markets framework and is subject to Nasdaq’s listing standards, including minimum bid price requirements for continued listing of its securities.

Average Trading Volume: 3,577,894

Technical Sentiment Signal: Sell

Current Market Cap: $4.28M

For an in-depth examination of SXTP stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1